Search

Displaying results 6261 - 6270 of 7479 in total
  1. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  2. Drug

    Elbimilast

    go.drugbank.com/drugs/DB20663
    Investigational

    Elbimilast has a monoisotopic molecular weight of 442.04 Da.

  3. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology of Alzheimer’s disease. Leca...

  4. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  5. Drug

    Alteminostat

    go.drugbank.com/drugs/DB19620
    Investigational

    Alteminostat has a monoisotopic molecular weight of 492.28 Da.

  6. Drug

    Gemilukast

    go.drugbank.com/drugs/DB19882
    Investigational

    Gemilukast has a monoisotopic molecular weight of 601.26 Da.

  7. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant has a monoisotopic molecular weight of 446.25 Da.

  8. Drug

    Idetrexed

    go.drugbank.com/drugs/DB21469
    Investigational

    Idetrexed has a monoisotopic molecular weight of 647.22 Da.

  9. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that

  10. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.